证券代码：000028 、200028 证券简称：国药一致、一致B 公告编号：2025-17 国药集团一致药业股份有限公司 关于2024年度利润分配方案的公告 本公司及董事全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、审议程序 2025 年 4 月 3 日，国药集团一致药业股份有限公司（以下简称"公司"） 第十届董事会第四次会议审议通过了《公司 2024 年度利润分配方案》，表 决结果：同意 7 票，反对 0 票，弃权 0 票。本议案尚需提交公司 2024 年 年度股东大会审议。 二、利润分配预案的基本情况 经天健会计师事务所（特殊普通合伙）审计确认，公司 2024 年度合并 会计报表归属于母公司股东的净利润为人民币 642,493,449.76 元，2024 年 末合并报表未分配利润为人民币 12,575,550,286.60 元，母公司会计报表净 利润为人民币 1,016,628,471.49 元。 根据《公司法》和本《公司章程》的有关规定，利润分配以母公司会 计报表净利润人民币 1,016,628,471.49 元为基准，加上年初未分配利润人民 币 7,504, ...

Financial Performance - The company's basic earnings per share decreased to 1.15 yuan, a decline of 59.93% compared to 2.87 yuan in the previous year [1] - Net profit fell to 6.42 billion yuan, down 59.85% from 15.99 billion yuan in the previous year [1] - Operating revenue slightly decreased to 74.378 billion yuan, a reduction of 1.46% from 75.477 billion yuan in the previous year [1] - Return on equity dropped to 3.67%, down 61.61% from 9.56% in the previous year [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 35,592.8 million shares, accounting for 64.79% of the circulating shares, with a decrease of 599.67 million shares compared to the previous period [2] - The largest shareholder, China National Pharmaceutical Group Corporation, holds 30,484.25 million shares, maintaining its position [3] - New entrants among the top shareholders include several investment funds, indicating a shift in the shareholder composition [3] Dividend Distribution - The company announced a dividend distribution of 3.66 yuan per share (including tax) [4]

Financial Performance - The company reported a revenue of CNY 74.38 billion for 2024, a decrease of 1.46% compared to CNY 75.48 billion in 2023[15]. - Net profit attributable to shareholders was CNY 642.49 million, down 59.83% from CNY 1.60 billion in the previous year[15]. - The basic earnings per share decreased to CNY 1.15, a decline of 59.93% from CNY 2.87 in 2023[15]. - The company’s total assets at the end of 2024 were CNY 47.56 billion, a slight decrease of 0.03% from CNY 47.57 billion in 2023[15]. - Operating cash flow increased by 11.38% to CNY 3.27 billion, compared to CNY 2.94 billion in 2023[15]. - The weighted average return on equity decreased by 5.89 percentage points to 3.67% from 9.56% in the previous year[15]. - The company's total revenue for Q1 2024 was approximately ¥19.09 billion, showing a decline to ¥17.91 billion in Q4 2024, representing a decrease of about 6.2% quarter-over-quarter[19]. - The net profit attributable to shareholders for Q1 2024 was approximately ¥388.77 million, which fell to a loss of ¥423.05 million in Q4 2024, indicating a significant decline in profitability[19]. - The cash flow from operating activities showed a positive net amount of approximately ¥1.99 billion in Q4 2024, recovering from a negative cash flow of approximately ¥634.15 million in Q1 2024[19]. - The company achieved operating revenue of 74.378 billion yuan in 2024, a year-on-year decrease of 1.46%[44]. - The net profit attributable to shareholders was 642 million yuan, down 59.83% year-on-year[44]. - The distribution segment generated operating revenue of 52.984 billion yuan, an increase of 1.98% year-on-year, while the retail segment (Guoda Pharmacy) reported revenue of 22.357 billion yuan, a decline of 8.41%[45]. - The company recorded a net cash flow from operating activities of 3.271 billion yuan, an increase of 11.38% year-on-year[46]. - The asset-liability ratio at the end of the reporting period was 56.36%, an increase of 0.46 percentage points year-on-year[51]. - The company reported a weighted average return on net assets of 3.67%, a decrease of 5.89 percentage points year-on-year[44]. - The company’s cash ratio improved to 0.29, indicating enhanced short-term solvency and risk management capabilities[51]. Market Challenges - The decline in profit was attributed to increased market competition and changes in industry policies affecting the retail sector[15]. - The company is facing challenges from the ongoing medical insurance payment reforms and centralized procurement policies, which are compressing profit margins and increasing competition[26]. - The pharmaceutical distribution industry is projected to see a 1.2% year-over-year decline in drug sales, with an estimated total sales of ¥186.38 billion in 2024[25]. - The implementation of DRG/DIP payment reform is prompting the company to adjust its operational strategies, emphasizing cost control and optimizing product structure[29]. - The government has introduced stricter regulations on medical insurance fund management, requiring the company to enhance compliance and internal management practices[31]. - The company anticipates challenges in profitability due to increased market competition and regulatory impacts on operational efficiency in both distribution and retail sectors[106]. Strategic Initiatives - The company is focusing on enhancing its supply chain and retail capabilities, aiming to establish a leading smart supply chain value system and a professional retail brand for prescription drugs[32]. - The company is investing in digitalization and smart technologies to improve operational efficiency and meet the evolving demands of the pharmaceutical distribution market[25]. - The company aims to enhance overall competitiveness through the collaborative development of three major business segments, focusing on high-margin and high-growth products[109]. - The retail segment plans to achieve digital transformation and diversify its operations, with a focus on improving operational quality and closing unprofitable stores[109]. - The company is committed to leveraging technology to optimize supply chain management and reduce costs, providing customized solutions to maintain competitive advantages[102]. Governance and Compliance - The company has established a comprehensive internal control system covering governance, management control, financial control, and operational management, ensuring compliance with relevant laws and regulations[158]. - The company has improved its governance structure by revising internal control systems and enhancing management quality[115]. - The company maintains complete independence from its controlling shareholders in business, personnel, and financial aspects[116]. - The company has a clear separation of assets from its controlling shareholders, ensuring independent operations[117]. - The company has established independent financial departments and tax compliance systems[117]. - The company has committed to improving investor relations and information disclosure practices[115]. - The company is committed to maintaining compliance and governance standards through its newly appointed legal and compliance officers[123]. Employee and Talent Management - The total number of employees at the end of the reporting period is 34,831, with 127 from the parent company and 34,704 from major subsidiaries[147]. - The professional composition includes 26,670 sales personnel, 15 production personnel, 409 technical personnel, 709 financial personnel, and 197 administrative personnel[147]. - The company emphasizes a dual approach of "internal cultivation and external recruitment" to enhance talent development and ensure a sustainable talent supply chain[150]. - The company has implemented a "Potential Dragon Plan" for talent development, focusing on a comprehensive training chain to cultivate backup talent[151]. - The company has established a multi-level and multi-type employee training system to promote comprehensive skill enhancement among employees[152]. Environmental Management - The company has established a comprehensive environmental monitoring system, enhancing the management efficiency of pollution control facilities[165]. - The company has implemented a complete environmental management system to ensure compliance with environmental laws and regulations for construction projects[166]. - Emergency response plans for environmental pollution incidents have been developed and regularly practiced to improve the company's emergency handling capabilities[167]. - The company reported no administrative penalties for environmental issues during the reporting period[164]. - The company has taken measures to reduce carbon emissions, as detailed in the 2024 ESG report[169]. Related Party Transactions - The company reported that related party purchases accounted for 83.62% of the total expected amount for the year, while related party sales accounted for 68.72%[187]. - Related party services provided accounted for 86.03% of the total expected amount, and services received accounted for 77.01%[187]. - The total amount of related party transactions across various categories accounted for 81.55% of the total expected amount for the year[187]. - The company has a maximum daily deposit limit of CNY 30,000,000 with its related party financial company, with a deposit interest rate of 0.35%[191]. - The company had a loan limit of CNY 120,000,000 with its related party financial company, with an interest rate range of 2.35% to 2.90%[191]. Management Changes - The company experienced significant management changes, with multiple directors and executives resigning or being appointed throughout 2024[123]. - The company is expanding its leadership team with new appointments, including several Vice General Managers and independent directors[123]. - The company has a focus on enhancing its governance structure with the election of new independent directors in July 2024[123]. - The current chairman, Wu Yijian, has been in position since November 13, 2020[121]. - Lin Min resigned as Chairman on January 18, 2024, and as a Director on February 18, 2024, due to work arrangement adjustments[123].

[ T able_StockInfo] 2025 年 03 月 20 日 证券研究报告•2024 年业绩快报点评 国药一致（000028）医药生物 目标价：33.18 元（6 个月） 买入 （维持） 当前价：26.27 元 商誉减值致短期承压，2025 年经营有望改善 | 指标/年度 | 2023A | 2024E | 2025E | 2026E | | --- | --- | --- | --- | --- | | 营业收入（百万元） | 75477.48 | 74378.49 | 78097.42 | 83564.24 | | 增长率 | 2.77% | -1.46% | 5.00% | 7.00% | | 归属母公司净利润（百万元） | 1599.26 | 642.49 | 1318.46 | 1492.62 | | 增长率 | 7.57% | -59.83% | 105.21% | 13.21% | | 每股收益 EPS（元） | 2.87 | 1.15 | 2.37 | 2.68 | | 净资产收益率 ROE | 9.34% | 3.91% | 7.03% | 7.48% | | PE | 9 | ...

证券代码：000028 、200028 证券简称：国药一致、一致B 公告编号：2025-12 国药集团一致药业股份有限公司（以下简称"公司"）于 2025 年 3 月 14 日召开第十届董事会 2025 年第四次临时会议，审议通过了 《关于拟计提资产减值准备的议案》,根据《深圳证券交易所股票上市 规则》等相关规定，现将公司计提资产减值准备的具体情况公告如下： 关于计提资产减值准备的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据《企业会计准则》、《深圳证券交易所股票上市规则》以及 公司会计政策等相关规定，为了更加客观真实反映公司截至 2024 年 12 月 31 日的财务状况和资产价值，基于谨慎性原则，公司 2024 年 度相关资产拟计提的资产减值准备情况如下： 一、本次拟计提资产减值准备情况概述 国药集团一致药业股份有限公司 根据《企业会计准则》及公司会计政策相关规定，基于谨慎性原 则，公司对合并报表范围内各类资产进行了检查和分析，对可能发 生资产减值损失的相关资产拟计提减值准备。具体情况如下表所 示： 单位：人民币万元 | 类别 | 项目 | 拟 ...

证券代码：000028 、200028 证券简称：国药一致、一致B 公告编号：2025-11 国药集团一致药业股份有限公司 第十届监事会2025年第一次临时会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 国药集团一致药业股份有限公司（以下简称"公司"）第十届监事 会 2025 年第一次临时会议于 2025 年 3 月 11 日以电话和电子邮件方 式发出通知和文件材料，于 2025 年 3 月 14 日以通讯表决方式召开。 应参加会议监事 3 名，实际出席会议监事 3 名。会议召开程序符合《公 司法》、《公司章程》的有关规定。 二、监事会会议审议情况 本次会议审议通过了《关于拟计提资产减值准备的议案》。 监事会认为公司基于谨慎性原则计提各项减值准备，符合《企业 会计准则》和公司会计政策相关规定，符合公司实际情况；能够公允 地反映公司的资产状况，不存在损害公司和股东合法利益的情况；本 次计提资产减值准备事项的决策程序符合相关法律法规的规定。 国药集团一致药业股份有限公司监事会 2025 年 3 月 18 日 表决结果：同意 3 ...

证券代码：000028 、200028 证券简称：国药一致、一致B 公告编号：2025-10 国药集团一致药业股份有限公司 第十届董事会2025年第四次临时会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 国药集团一致药业股份有限公司（以下简称"公司"）第十届董事 会 2025 年第四次临时会议于 2025 年 3 月 11 日以电话和电子邮件方 式发出通知和文件材料，于 2025 年 3 月 14 日以通讯表决方式召开。 应参加会议董事 7 名，实际出席会议董事 7 名。会议召开程序符合《公 司法》、《公司章程》的有关规定。 二、董事会会议审议情况 本次会议审议通过了《关于拟计提资产减值准备的议案》。 董事会同意公司根据《企业会计准则》及公司会计政策的相关规 定，2024 年度共计提减值准备 109,385.73 万元。公司本次资产减值 准备计提符合《企业会计准则》和公司相关会计政策的规定，本次计 提资产减值准备基于谨慎性原则，依据充分，能够真实地反映公司的 财务状况及经营成果。 表决结果：同意 7 票，反对 0 票、弃权 ...

Financial Performance - Total revenue for 2024 was CNY 74.38 billion, a decrease of 1.46% year-on-year[3] - Operating profit fell to CNY 5.73 billion, down 76.76% compared to the previous year[3] - Net profit attributable to shareholders decreased to CNY 6.42 billion, a decline of 59.83% year-on-year[3] - Basic earnings per share dropped to CNY 1.15, reflecting a 59.93% decrease from the prior year[3] - The weighted average return on equity decreased by 5.89 percentage points to 3.67%[3] Segment Performance - The distribution segment achieved revenue of CNY 52.98 billion, an increase of 1.98% year-on-year[6] - The retail segment reported revenue of CNY 22.36 billion, a decline of 8.41% year-on-year[6] Asset and Equity - Total assets at the end of the reporting period were CNY 475.56 billion, a slight decrease of 0.03%[3] - Shareholders' equity attributable to the parent company increased by 1.46% to CNY 176.70 billion[3] Impairment - The company recognized an impairment provision of CNY 970 million for goodwill and intangible assets, impacting net profit by CNY 561 million[6]

证券代码：000028 、200028 证券简称：国药一致、一致B 公告编号：2025-09 国药集团一致药业股份有限公司 第十届董事会2025年第三次临时会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 王矗先生符合《公司法》等相关法律法规、规范性文件、《深 圳证券交易所股票上市规则》及深交所其他相关规定等要求的任 职条件，简历后附。 表决结果：同意 7 票，反对 0 票、弃权 0 票。 特此公告。 国药集团一致药业股份有限公司董事会 2025 年 3 月 6 日 附：简历 王矗先生，1979 年出生，中国国籍，中共党员，硕士研究生， 药师。国药控股广州有限公司（简称"国控广州"）党委副书记、总 经理。2003 年至 2006 年，广东省医药协会科技质量部工作；2012 年 至 2019 年，先后任国控广州省外商业销售部销售代表、大区经理、 商业拓展部副总监、商业营运部总监、商业销售中心副总经理、国药 控股广东恒兴有限公司总经理；2019 年至 2021 年，任国控广州副总 经理；2021 年 9 月起，任国控广州总经理； ...

国药一致公司章程 - 1 - 国药集团一致药业股份有限公司 章 程 国药一致公司章程 - 2 - 目 录 第一章 总则 第二章 经营宗旨和范围 第三章 股份 第一节 股份发行 第二节 股份增减和回购 第三节 股份转让 第四章 股东和股东大会 第一节 股东 第二节 股东大会的一般规定 第三节 股东大会的召集 第四节 股东大会的提案与通知 第五节 股东大会的召开 第六节 股东大会的表决和决议 第五章 公司党组织 第六章 董事会 第一节 董事 第二节 董事会 第七章 总经理及其他高级管理人员 第八章 监事会 第一节 监事 第二节 监事会 第九章 财务会计制度、利润分配和审计 第一节 财务会计制度 第二节 内部审计 第三节 会计师事务所的聘任 第十章 通知与公告 第一节 通知 第二节 公告 第十一章 合并、分立、增资、减资、解散和清算 第一节 合并、分立、增资和减资 第二节 解散和清算 第十二章 修改章程 第十三章 附则 国药一致公司章程 - 3 - 第一章 总则 第一条 为规范公司的组织和行为，全面贯彻落实"两个一以贯之"重要要 求，坚持和加强党的全面领导，完善公司法人治理结构，建设中国特色现代企业 制度，维护公司 ...